An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation

被引：1
|
作者：
Tan, Daniel
Goto, Koichi
Loong, Herbert Hf
Yang, Tsung-Ying
Gadgeel, Shirish
Massarelli, Erminia
Daniele, Gennaro
Le, Xiuning
Shinno, Yuki
Murakami, Haruyasu
Sakamoto, Tomohiro
Ruffinelli, Jose C.
Lu, Shun
Zhang, Yiping
Kim, Tae Min
Brennan, Barbara J.
Chen, Chunlin
Joosten, Miranda
Wang, Zebin
Pu, Su-Fen
Bao, Weichao
Kornacker, Martin
Ferraldeschi, Roberta
Grassi, Paolo
Goh, Boon Cher
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT126
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Preclinical activity of BAY 2927088 in HER2 mutant non-small cell lung cancer
    Siegel, Franziska
    Karsli-Uzunbas, Gizem
    Kotynkova, Kristyna
    McVeigh, Quinn
    Siegel, Stephan
    Korr, Daniel
    Schulze, Volker
    Berger, Markus
    Beckmann, Georg
    Cherniack, Andrew
    Meyerson, Matthew
    Greulich, Heidi
    CANCER RESEARCH, 2023, 83 (07)
  • [2] Trial in progress: First-in-human study of BBT-207 in advanced non-small cell lung cancer harboring EGFR mutation after treatment with EGFR TKI
    Jeon, NaEun
    Spira, Alexander
    Orr, Douglas
    Bazhenova, Lyudmila
    Nagasaka, Misako
    Ahn, Jin Seok
    Kim, Dong-Wan
    Kim, Yu Jung
    Cho, Jimin
    Jung, Agnes
    Jung, Eunsoo
    Kim, Chul-Won
    Jin, Taiguang
    Lee, Yong-Hee
    Lee, Sang-Yoon
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [3] EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
    Cappuzzo, Federico
    Ligorio, Claudio
    Toschi, Luca
    Rossi, Elisa
    Trisolini, Rocco
    Paioli, Daniela
    Magrini, Elisabetta
    Finocchiaro, Giovanna
    Bartolini, Stefania
    Cancellieri, Alessandra
    Hirsch, Fred R.
    Crino, Lucio
    Varella-Garcia, Marileila
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (05) : 423 - 429
  • [4] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
    An, Chaolun
    Zhang, Jiajun
    Chu, Hongjun
    Gu, Chunyan
    Xiao, Feng
    Zhu, Fengwei
    Lu, Rujian
    Shi, Hai
    Zhang, Hongfei
    Yi, Xin
    PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
  • [5] Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial
    Fang, Wenfeng
    Zhao, Yuanyuan
    Huang, Yan
    Zhang, Yaxiong
    Hong, Shaodong
    Huang, Yihua
    Zhao, Hongyun
    Yang, Yunpeng
    Zhao, Shen
    Chen, Gang
    Zhou, Huaqiang
    Ma, Yuxiang
    Zhou, Ningning
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] The patients' characteristics and the clinical outcomes in advanced non-small cell lung cancer patients with HER2 mutation
    Liao, Pei-Ya
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Tseng, Jeng-Sen
    Lee, Po-Hsin
    Yang, Tsung-Ying
    RESPIROLOGY, 2023, 28 : 297 - 297
  • [7] First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer
    Cheng, Haiying
    Zou, Yiyu
    Shah, Chirag D.
    Fan, Ni
    Bhagat, Tushar D.
    Gucalp, Rasim
    Kim, Mimi
    Verma, Amit
    Piperdi, Bilal
    Spivack, Simon D.
    Halmos, Balazs
    Perez-Soler, Roman
    LUNG CANCER, 2021, 154 : 99 - 104
  • [8] Efficacy and safety study of osimertinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation
    Garcia Samblas, Victoria
    Fernandez Madrigal, Laura
    Rodriguez Garces, Maria Yeray
    Inoriza, Angel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Exclusive mutation in EGFR, HER2, and KRAS, and synchronous methylation of non-small cell lung cancer
    Suzuki, Makoto
    Shigematsu, Hisayuki
    Iizasa, Toshihiko
    Minna, John D.
    Fujisawa, Takehiko
    Gazdar, Adi F.
    CANCER RESEARCH, 2006, 66 (08)
  • [10] Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study
    Puyuan Xing
    Qian Zhao
    Li Zhang
    Hanping Wang
    Dingzhi Huang
    Pei Hu
    Yinghui Sun
    Yuankai Shi
    BMC Medicine, 20
12345